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Background: Physical activity and health status deteriorate early in the course of chronic
obstructive pulmonary disease (COPD). This can only partially be explained by the degree of
airflow limitation. Changes in (resting and dynamic) lung volumes are known to be associated
with functional impairments and thus might influence physical activity level. The aim of the
present cross-sectional study was to explore the contribution of dynamic hyperinflation during
daily life activities (ADL) in the decline in physical activity.
Methods: Airflow limitation and inspiratory capacity at rest to total lung capacity ratio
(IC/TLC) as a measure of resting hyperinflation were measured in 59 patients with COPD (GOLD
IeIV). Mean daily physical activity was assessed with a tri-axial accelerometer. Measurements
of dynamic hyperinflation during ADL (DIC and inspiratory reserve volume at end ADL) were
performed at patients’ home using a portable breath-by-breath system.
Results: Multiple regression analysis showed that resting as well as ADL-induced dynamic
hyperinflation independently contributed to decreased daily physical activity, together
explaining 45.8% of the variance in physical activity. In contrast to hyperinflation, the severity
of airflow limitation (FEV1) appeared to have no unique part in explaining how physically (in-)
active patients were.umcn.nl, alahaije@hotmail.nl (A.J.M.C. Lahaije), H.vanHelvoort@long.umcn.nl (H.A.C. van Helvoort),
ekhuijzen), J.Vercoulen@mps.umcn.nl (J.H. Vercoulen), Y.Heijdra@long.umcn.nl (Y.F. Heijdra).
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Hyperinflation and physical activity 835Conclusions: The presence of resting hyperinflation and occurrence of dynamic hyperinflation
during ADL contribute to reduced physical activity levels in patients with COPD, independently
of the degree of airflow limitation.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Deterioration in physical activity level and health status (HS)
in patients with chronic obstructive pulmonary disease
(COPD) are important patient related outcomes, which not
necessarily follow the progressive airflow limitation that
characterizes the disease. Although physical activity level
declines with worsening of airflow limitation, there is great
variability in physical activity as well as in HSwithin a certain
degree of airflow limitation.1e3 Part of the variability in
physical activity might be explained by dynamic hyperinfla-
tion. Dynamic hyperinflation as well as the subsequent
decrease in inspiratory reserve volume (IRV) is known to
induce dyspnea and to limit exercise capacity in COPD.4 One
study showed that patients who hyperinflated during car-
diopulmonary exercise testing had a lower level of physical
activity than patients who did not hyperinflate.5 Although
ADL is less likely to require maximal exercise capacity, it has
been shown that dynamic hyperinflation also occurs during
dyspnea-causing activities of daily life (ADL).6,7 A certain
amount of dynamic hyperinflation may be accommodated
when inspiratory capacity (IC) is preserved. But patients also
may have resting hyperinflation due to the changes in lung
compliance associated with COPD. This leaves them less
room for dynamic hyperinflation and a critical decrease in
inspiratory reserve volume (IRV) may occur even during ADL.
Whether hyperinflation or a decrease in IRV during ADL is
associated with physical inactivity is unknown. We hypoth-
esized that patients who are less active would experience
more hyperinflation during daily life activities (ADL).
The aim of the present study was to investigate whether
ADL-induceddynamic hyperinflation additionally explains the
level of physical activity in patients with COPD, next to the
variance that can be explained by FEV1. Because it depends
on the amount of resting hyperinflation and the remaining IRV
if dynamic hyperinflation leads to mechanical constraints,
these factors were included in the analysis. Therefore, we
measured physical activity level with an electronic acceler-
ometer and measured dynamic hyperinflation and IRV during
dyspnea-causing ADL. Additionally, we investigated the re-
lations between physical activity level and HS.
Materials and methods
Subjects
Between November 2009 and March 2012, 57 patients were
recruited from the outpatient population of the Radboud
University Nijmegen Medical Centre and the University
Centre for Chronic Diseases Dekkerswald and from general
practices in close proximity of Nijmegen, The Netherlands.
Inclusion criteria were a diagnosis of COPD and clinical
stability, defined as no exacerbations for at least 6 weeks.Exclusion criteria were other respiratory diseases, long
term oxygen therapy, recent participation in a pulmonary
rehabilitation program and disorders which could possibly
interfere with exercise testing (severe or unstable heart
disease, neuromuscular or musculoskeletal disorders).
The study was approved by the local Medical Research
Ethics Committee (CMO Arnhem-Nijmegen, no NL25920.
091.08) and all patients gave their written informed consent.
During a visit to the hospital, pulmonary function was
measured according to the guidelines of the American
Thoracic Society and European Respiratory Society.8e10
Reference equations for the calculation of predicted
values were those produced by the European Community for
Steel and Coal.11 Severity of airflow limitation was classified
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stages.12 Predicted normal values for
inspiratory capacity (IC) were calculated as predicted total
lung capacity (TLC) minus predicted functional residual ca-
pacity (FRC). Because TLC aswell as FRCmay increase due to
changing lung compliance associated with COPD, thus pre-
serving IC, the ratio between IC and TLC was used to reflect
resting hyperinflation. Maximal voluntary ventilation (MVV)
was estimated at 37.5  FEV1.13 Additionally, a symptom-
limited cardiopulmonary bicycle exercise test was per-
formed to assess maximal exercise capacity.13
ADL assessment was performed during a visit at patients’
home, within ten days from the hospital visit. Patients
selected their individual most dyspnea-causing activity and
performed this ADL until symptom limitation, task comple-
tion or for a maximum of 10 min. Measurements during ADL
were performed using a portable breath-by-breath system
(Oxycon Mobile, Jaeger, CareFusion GmbH, Hoechberg,
Germany).7 This system also allows investigators to reliably
track changes in IC, which reflect changes in end-expiratory
lung volume due to dynamic hyperinflation.14 IC was
measured at rest9 and at the end of ADL. The change in IC
relative to resting IC (%DICZ (IC end IC rest)/IC rest 100)
was used to reflect the amount of dynamic hyperinflation. IRV
was calculated as the difference between IC and tidal volume
(VT) at end ADL and expressed as percentage of TLC. To
quantify oxygen consumption (VO2), heart rate, minute
ventilation (VE), VT and peripheral oxygen saturation (SpO2)
the mean values of the last minute of ADL were used. ADL-
induced dyspnea was measured with a Borg scale.
Between the hospital visit and ADL testing, patients
wore a tri-axial accelerometer (Actometer)15 for seven
consecutive days to assess mean daily physical activity. The
accelerometer was worn at the ankle and users were asked
to wear the device day and night, except during showering,
swimming etc. Minimal wearing time is 22 out of 24 h for a
day to be included in the analyses. Mean physical activity
was expressed as vector magnitude units (VMU).
HS was assessed by the Nijmegen Clinical Screening
Instrument (NCSI), a validated instrument, described
Table 1 Characteristics of the study population (n Z 57
patients).
Mean  sd
Anthropometrics
Age, year 64.1  7.1
Sex, M/F 35/22
Weight, kg 79.3  17.2
Height, cm 171.1  8.0
BMI, kg/m2 27.0  5.0
Pulmonary function
GOLD stage I/II/III/IV, n 15/22/14/6
FEV1 post-bronchodilator,
L (%pred)
1.81  0.74 (64  24)
FEV1/FVC post-bronchodilator, % 46  14
TLC, L (%pred) 7.27  1.48 (114  22)
RV, L (%pred) 3.55  1.07 (153  43)
IC/TLC, % 38  9
RV/TLC, % 49  10
DLCO, %pred 58  24
Exercise capacity
Peak work load, W 106  45
Peak VO2, L/min (%pred) 1.54  0.52 (81  21)
Peak VE, L/min (%MVV) 58.9  17.8 (90  24)
Peak HR, beats/min 137  18
Dyspnea (Borg) 6.6  2.2
Leg discomfort (Borg) 5.4  2.2
BMI: body mass index; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; TLC: total lung capacity; RV: resid-
ual volume; IC: inspiratory capacity; DLCO: diffusion capacity of
the lung for carbon monoxide; VO2: oxygen consumption; VE:
minute ventilation; MVV: maximal voluntary ventilation; HR:
heart rate; %pred: percentage of predicted normal values.
Figure 1 Physical activity data of the individual subjects per
GOLD stage.
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physiological functioning, symptoms, functional impairment
in daily life and quality of life as main domains.17,18 These
domains were shown empirically to be subdivided into many
independent sub-domains.19 The NCSI is an empirically
composed battery of validated generic and disease-specific
instruments that provide a detailed and comprehensive
assessment of these sub-domains of HS. In the present study,
the NCSI covered eight sub-domains of the main domains
‘symptoms’, ‘functional impairment’ and ‘quality of life’. For
each sub-domain, the scores of the respective instruments
were summed to a sub-domain total score. Based on norma-
tive data of healthy subjects and patients with COPD, these
sub-domain total scores indicated normal functioning, mild
problems or severe problems for each sub-domain.16 This al-
lows HS evaluation on the level of the individual patient.
Statistical analyses
The One-Sample KolmogoroveSmirnov Test was used to
verify normal distribution of the variables. Normally
distributed data are expressed as mean  standard devia-
tion. Distribution of categorical variables is described in
numbers and percentages. Pearson correlations were used
to investigate univariate associations between physical
activity on the one hand and FEV1%pred, resting hyperin-
flation (ICrest/TLC), ADL-induced dynamic hyperinflation
(%DIC) and IRV/TLC at end ADL on the other hand.
The impact of ICrest/TLC, %DIC and IRV/TLC at end ADL
on physical activity was analyzed by performing standard
multiple linear regression analyses. First, we analyzed FEV1
(%pred) as explanatory variable for physical activity. Then,
ICrest/TLC, %DIC and IRV/TLC at end ADL were added in a
second model to evaluate whether they additionally
explained the variance in physical activity. Statistical sig-
nificance was set at a p-value < 0.05.
Results
Characteristics
In Table 1, anthropometrics, pulmonary function and exercise
capacity of the study population are described. Age ranged
from 48 to 77 years and 63% of the patients was male. Twenty
percent of the patients was current smoker. Forty-two
percent of the patients used either short- or long-acting b2-
agonists, 73% used anticholinergics, 10% used a combination
preparation of b2-agonist and anticholinergic, and 71% used
inhaled corticosteroids.
Level of physical activity and health status
Mean activity level was 39.8  12.2 vector magnitude units
(range 12e70). Fig. 1 depicts the large variance in physical
activity within GOLD stages.
The number of patients experiencing normal functioning,
mild or severe problems respectively for each sub-domain
of HS are described in Table 2. Seventy-eight percent of the
patients experienced severe problems in one or more sub-
domains of HS.The fact that there are patients without severe prob-
lems in any sub-domain, but also patients with severe
problems in all sub-domains, shows that there was a large
heterogeneity regarding HS in this population.
Measurements during ADL
Patients chose different dyspnea-causing activities.
These ADL varied from household activities to gardening
Table 2 The number of patients experiencing normal functioning, mild or severe problems in each sub-domain of the Nij-
megen Clinical Screening Instrument.
Main domain Normal scores Mild problems Severe problems
Sub-domain (normal, mild problems, severe problems) N (%) N (%) N (%)
Symptoms
Subjective pulmonary symptoms (2, >29, >9) 3 (5) 26 (46) 28 (49)
Dyspnea emotions (8, >8<12, 12) 20 (35) 19 (33) 18 (32)
Fatigue (<27, 27<35, 35) 14 (25) 13 (234) 30 (53)
Functional impairment
Behavioral impairment (2.91, >2.9117.38, >17.38) 14 (25) 26 (46) 17 (30)
Subjective impairment (4, >411, >11) 2 (4) 26 (46) 29 (51)
Quality of life
General quality of life (11.36, >11.36) 22 (39) e 35 (61)
Health-related quality of life (3, >35, >5) 19 (33) 24 (42) 14 (25)
Satisfaction relations (2, >24, >4) 28 (49) 20 (35) 9 (16)
For each sub-domain of HS the cut-off values for normal scores, mild problems and severe problems are described between brackets.16
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07:51  02:53 min. Mean dyspnea score at end ADL was 5.1
on the Borg scale and varied between 0.5 and 10 (DBorg
3.6  2.0). Physiologic responses to ADL are presented in
Table 3. Eighteen percent of the patients (N Z 10) had a
decreased breathing reserve (VE/MVV > 0.85 and/or MVV-
VE < 11L) during ADL. In 32% of the patients (N Z 18) IRV
decreased to less than 0.5L20 or less than 10% of TLC.13
Oxygen desaturation (DSpO2  4%) during ADL occurred
in 20 patients; only one patient had SpO2  80% at end ADL.
Associations
Mean daily physical activity was associated with airflow
limitation (FEV1%pred) and ICrest/TLC as well as with %DIC
and IRV/TLC at end ADL (Table 4).
Table 5 shows the changes in total variance (R2) with
these variables added into the multiple regression model,
as well as the contribution of each independent variable toTable 3 Measurements at start and end of ADL.
Rest End ADL
Borg score, au 1.5  1.4 5.1  2.3
VO2, L/min (%pred) 0.34  0.07
(18.9  5.9)
1.09  0.32
(59.1  16.5)
HRR, bpm 79.7  13.8 54.5  15.6
VE, L/min (%MVV) 13.8  3.4
(23.8  10.8)
34.9  8.2
(57.7  18.9)
IC, L 2.76  0.77 2.37  0.79
DIC, %IC rest e 14.1  15.4
IRV, L (%TLC) 1.82  0.63
(25.4  7.6)
0.98  0.52
(13.8  6.9)
SpO2, % 96.2  2.5 92.8  5.5
Mean  sd. Au: arbitrary units; VO2: oxygen uptake; HRR: heart
rate reserve (Z 220heart rate); VE: minute ventilation; MVV:
maximal voluntary ventilation; DIC: change in inspiratory ca-
pacity from rest; IRV: inspiratory reserve volume; TLC: total
lung capacity; SpO2: oxygen saturation.the variance in physical activity (B). In the first model
FEV1%pred explained 24.5% of R
2 in daily physical activity in
the study population. The second model explained an
additional 21.3% of R2. However, in this second model,
FEV1%pred and IRV/TLC appeared to have no unique part in
physical activity (p Z 0.939 and p Z 0.940 respectively).
Resting and dynamic hyperinflation were independent
explanatory variables (p < 0.05 for B). This means that
resting and dynamic hyperinflation explained 45.8% of the
variance in physical activity (R Z 0.677).
Analyses of the relationships between physical activity
and sub-domains of HS showed significant associations in all
domains except for the sub-domains of ‘fatigue’ and
‘satisfaction with relations’. The strongest association was
found between physical activity and ‘behavioural impair-
ments’ (rZ 0.56, p < 0.001). A more detailed description
can be found in e-Table 2.
Discussion
This study shows that both resting hyperinflation and ADL-
induced dynamic hyperinflation uniquely contribute to a
lower level of physical activity in patients with COPD.
In other words, the large variance in physical activity within
patients with a given level of FEV1 can partially beTable 4 Pearson’s correlation coefficients for the relation
between physical activity and possible determinants.
Physical activity 95% CI
FEV1 (%pred) 0.50
# 0.27e0.67
ICrest/TLC 0.60# 0.40e0.74
%DIC 0.42* 0.18e0.61
IRV/TLC 0.57# 0.36e0.72
FEV1: forced expiratory volume in 1 s; ICrest/TLC: ratio be-
tween inspiratory capacity at rest and total lung capacity; DIC:
relative change from ICrest during ADL; IRV: inspiratory reserve
volume at end ADL; *p < 0.01; #p < 0.001; CI: confidence in-
terval of the correlation coefficient.
Table 5 Results of multiple regression analyses with mean daily physical activity as dependent variable.
Model Unstandardized coefficients p-value R2 R2 Change
B SE
(Constant) 23.611 4.128
FEV1%pred 0.255 0.061 <0.001
1 24.5% e
(Constant) 14.194 6.664
FEV1%pred 0.006 0.084 0.939
ICrest/TLC 78.546 24.677 0.002
%DIC 0.270 0.132 0.046
IRV/TLC 0.027 0.354 0.940
2 45.8% 21.3%
Independent determinants of physical activity in the models are marked by bold print of their respective p-values.
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patients have and the dynamic hyperinflation that occurs
during activities they perform in daily life. Additionally, a
lower level of physical activity appears to be associated
with worse health status.
The results showed that both resting hyperinflation and
ADL-induced dynamic hyperinflation together explain almost
46% of the variance in daily physical activity of patients with
COPD. With both measures for hyperinflation included in our
multivariate analysis, it appeared that severity of airflow
limitation does not have a unique contribution to patients’
level of physical activity. Garcia-Rio et al.,5 found lower
levels of physical activity in patients who hyperinflated
during incremental exercise testing, regardless of their
severity of airflow limitation. Following up on these results,
the present study now shows in real life that hyperinflation
during daily life activities is more relevant for physical ac-
tivity than airflow limitation. A characteristic feature of this
study is the fact that patients chose their individual most
dyspnea-causing activities themselves. Because patients
were asked to select ADL that they performed regularly, the
changes in lung volumes we observed are thus representa-
tive of regularly occurring phenomena.
Recently, several studies have indicated that a deteriora-
tion in physical activity starts early in the course of
COPD.2,3,21 So far, the reason for this decline is not completely
understood. Airflow limitation may play a role, but correla-
tions are weak to moderate and do not explain why deterio-
ration starts when FEV1 is still relatively preserved.
2,21,22 Due
to the difference in algorithms that are used to convert the
output signal of accelerometers into VMU’s, comparison of
the physical activity levels to other studies is limited. We
found a decline in physical activity with increasing GOLD
stage as well. Yet, with the large variance in physical activity
within GOLD stages and the major overlap between GOLD
stages, we could not show significant differences.
In earlier studies, we demonstrated that dynamic hy-
perinflation occurs during ADL6,7 and therefore we pre-
sumed a relationship between the amount of dynamic
hyperinflation induced during regularly performed activ-
ities in daily life and a decline in physical activity.
In general, patients with lower FEV1 tend to have more
resting hyperinflation,23,24 i.e. IC and thus IRV are alreadylower at rest. Any extra hyperinflation during physical activity
adds to the already elevated end-expiratory lung volume,
leaving less room for the expansion of tidal volume that
comes with increasing minute ventilation. In severe COPD
dynamic hyperinflation is likely to lead to such mechanical
constraints on tidal volume. At some point, further increase
in the effort to breathe does not result in an equal increase in
tidal volume, known as neuromechanical dissociation. This
causes a sharp increase in symptoms and impairments that
patients experience. In mild-to-moderate COPD this neuro-
mechanical dissociation not necessarily happens, because IC
is still large. Despite the fact that, in the present study, a
considerable amount of dynamic hyperinflation was shown
during ADL, a critical decrease in IRV (to less than 0.5L20 or
less than 10% of TLC13) occurred in onlyw30% of the subjects.
That might explain why lower IRV at the end of ADL did not
contribute to a lower level of physical activity, when FEV1 and
hyperinflation were already taken into account. Yet, an in-
crease in inspiratory effort due to the extra elastic and
threshold loading of the inspiratory muscles that comes with
(dynamic) hyperinflation most likely occurred.4,25 Especially
in patients who have less room to hyperinflate this increasing
effort might discourage them to maintain their activities.
This is supported by the final model in which both resting and
dynamic hyperinflation remain as a unique contributor to
mean daily physical activity.
Next to patients’ level of physical activity we measured
HS. Though the study population mainly consists of patients
withmild-to-moderate airflow limitation, 78% of the patients
experienced severe problems in one or more sub-domains of
HS. This is in line with a recent study of Jones et al., who also
foundmarked impairments in HS in patientswithmild COPD.1
Studies investigating HS showed that sub-domains of HS are
poorly related to airflow limitation.22 Physical activity,
important for maintaining health,26 was found to be an in-
dependent predictor of quality of life.27,28Whether there is a
causal relation between physical activity and sub-domains of
HS cannot be concluded from this cross-sectional study.
Clinical relevance
Because physical (in-) activity is related to hospitalization,
mortality and lung function decline29,30 and to the
Hyperinflation and physical activity 839occurrence of systemic effects31 and comorbidities,32 pro-
moting physical activity in patients with COPD is now rec-
ommended from an early stage of disease on.12 Most likely
physical inactivity causes deconditioning, leading to more
symptoms and impairments and thus more inactivity.33
Since the decrease in physical activity in patients with
COPD cannot be predicted by monitoring FEV1, it is
important to measure resting and operating lung volumes,
because these are significant contributors to physical ac-
tivity in COPD. Likely, the association between airflow
limitation and physical activity is mediated through the
amount of resting hyperinflation and the occurrence of
dynamic hyperinflation. Detecting the occurrence of dy-
namic hyperinflation during ADL is important, but may be
unfeasible in clinical practice. However, this can be
determined alternatively during CPET or voluntary hyper-
ventilation. Given that our results indicate that patients
who hyperinflate during their own daily activities might be
at risk of becoming inactive, early detection and treatment
of hyperinflation may be a key aspect in the prevention of
inactivity.
In conclusion, resting hyperinflation and the dynamic
hyperinflation that occurs during activities that patients
perform in daily life explain levels of physical activity in
patients with COPD better than FEV1. Therefore, hyperin-
flation deserves attention in the monitoring of patients with
COPD.
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